1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Yiviva Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) Sorafenib+YIV-906, Sorafenib+placebo - Advanced Hepatocellular Carcinoma | Phase 2 | Completed | Yiviva Inc. | 62 | 2020-01-10 | 2025-04-13 |
Carcinoma, Hepatocellular (1) · Hepatitis B (1)
PHY 906 (1)
China (1) · Hong Kong (1) · Taiwan (1) · United States (1)
Ghassan Abou-Alfa, MD/MBA (1) · Yun Yen, MD/PhD (1)
PMID 12620148, PMID 19846955, PMID 20092990, PMID 21859559, PMID 24297682